Laufer Joel, Scasso Santiago, Papadia Andrea
Department of Gynaecology, Gynecologic Oncology Unit, Hospital Británico, Montevideo 11600, Uruguay.
Department of Gynaecology, Gynecologic Oncology Unit, Hospital Casmu, Montevideo 11600, Uruguay.
Cancers (Basel). 2024 Sep 8;16(17):3107. doi: 10.3390/cancers16173107.
Over the past decade, SLN mapping has become increasingly important in cervical cancer surgery. ICG is the most commonly used tracer due to its high bilateral detection rates, ease of use, and safety. However, there is no consensus on the optimal ICG dose, leading to variability in outcomes. This systematic review aims to evaluate the impact of different ICG doses on SLN detection in early-stage cervical cancer, identifying the most effective and safe dose for clinical practice. A comprehensive search was conducted in MEDLINE/PubMed up to May 2024. Studies included assessed SLN mapping using ICG in stage IA2-IIA/IIB cervical cancer. Exclusions were applied to studies not reporting ICG dose or using multiple tracers without dose-specific results. Twelve studies were included, with ICG concentrations ranging from 0.25 mg/mL to 25 mg/mL and injection volumes from 1 to 10 mL. Overall SLN detection rates ranged from 88% to 100%, while bilateral detection rates varied between 74.1% and 98.5%. The most consistent results were obtained with an ICG concentration of 1.25 mg/mL and a 4 mL injection volume. In conclusion, an ICG concentration of 1.25 mg/mL with a 4 mL injection volume is recommended for effective SLN mapping in cervical cancer, achieving high detection rates with minimal variability. Standardizing this dose in clinical practice is suggested to improve reproducibility and outcomes.
在过去十年中,前哨淋巴结(SLN)定位在宫颈癌手术中变得越来越重要。吲哚菁绿(ICG)因其较高的双侧检测率、易用性和安全性,成为最常用的示踪剂。然而,对于ICG的最佳剂量尚无共识,导致结果存在差异。本系统评价旨在评估不同ICG剂量对早期宫颈癌SLN检测的影响,确定临床实践中最有效和安全的剂量。截至2024年5月,在MEDLINE/PubMed数据库中进行了全面检索。纳入的研究评估了在IA2-IIA/IIB期宫颈癌中使用ICG进行SLN定位的情况。排除未报告ICG剂量或使用多种示踪剂且无特定剂量结果的研究。共纳入12项研究,ICG浓度范围为0.25 mg/mL至25 mg/mL,注射体积为1至10 mL。总体SLN检测率为88%至100%,而双侧检测率在74.1%至98.5%之间。ICG浓度为1.25 mg/mL、注射体积为4 mL时获得的结果最为一致。总之,对于宫颈癌有效的SLN定位,建议使用ICG浓度为1.25 mg/mL、注射体积为4 mL,可实现高检测率且变异性最小。建议在临床实践中标准化该剂量,以提高可重复性和结果。